Cingulate(CING) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study of Lead Asset Ctx-1301 for Adhd
ReutersApr 29 08:00 ET
Cingulate Announces Positive Top-Line Results From High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
GlobeNewswireApr 29 08:00 ET
Cingulate Is Maintained at Buy by Ascendiant Capital
Dow JonesApr 21 06:44 ET · Ratings
Cingulate Analyst Ratings
BenzingaApr 21 06:30 ET · Ratings
Express News | Cingulate Inc : Ascendiant Capital Markets Cuts Target Price to $60 From $75
ReutersApr 21 02:25 ET
Analysts' Top Healthcare Picks: Healthequity (HQY), Cingulate Inc (CING)
TipRanksApr 11 07:50 ET · Ratings

Comments

Trytosaveabit

20 hours ago

news

$Cingulate (CING.US)$ Reuters· 6 mins ago
Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study of Lead Asset Ctx-1301 for Adhd

1

Jaguar8

20 hours ago

NEWS

$Cingulate (CING.US)$
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
Tuesday, 29th April at 8:00 am
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food
CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD
KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...

1

Trytosaveabit

Apr 9 20:01

news

$Cingulate (CING.US)$ Press Release: Cingulate Receives $3 Million Grant From Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (Buspirone)
Dow Jones· just
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Mar...

1

Trytosaveabit

Apr 3 20:01

news

$Cingulate (CING.US)$ Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
52 SECONDS AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it held a Pre-NDA meeting wi...

1